Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL60 vs bevacizumab plus paclitaxel + carboplatin in advanced nonsquamous NSCLC
CTR20170658Phase 3Completed
- Sponsor
- Mabworks Biotech
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bevanovis in non-small cell lung cancer (NSCLC), sponsored by Mabworks Biotech. Started Aug 2017; status: completed.
02
Drugs
Bevanovis
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170658.